Haematologica (Apr 2018)
Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population
- Claire Oudin,
- Julie Berbis,
- Yves Bertrand,
- Camille Vercasson,
- Frédérique Thomas,
- Pascal Chastagner,
- Stéphane Ducassou,
- Justyna Kanold,
- Marie-Dominique Tabone,
- Catherine Paillard,
- Marilyne Poirée,
- Dominique Plantaz,
- Jean-Hugues Dalle,
- Virginie Gandemer,
- Sandrine Thouvenin,
- Nicolas Sirvent,
- Paul Saultier,
- Sophie Béliard,
- Guy Leverger,
- André Baruchel,
- Pascal Auquier,
- Bruno Pannier,
- Gérard Michel
Affiliations
- Claire Oudin
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France;Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
- Julie Berbis
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
- Yves Bertrand
- Department of Pediatric Hematology and Oncology, University Hospital of Lyon, France
- Camille Vercasson
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
- Frédérique Thomas
- Preventive and Clinical Investigation Centre, Paris, France
- Pascal Chastagner
- Department of Pediatric Onco-Haematology, Children’s Hospital of Brabois, Vandoeuvre Les Nancy, France
- Stéphane Ducassou
- Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, France
- Justyna Kanold
- Department of Pediatric Hematology and Oncology, CIC Inserm 501, University Hospital of Clermont-Ferrand, France
- Marie-Dominique Tabone
- Pediatric Hematology Department, Trousseau Hospital, Paris, France
- Catherine Paillard
- Department of Pediatric Hematology-Oncology, University Hospital, Strasbourg, France
- Marilyne Poirée
- Pediatric Hematology and Oncology Department, University Hospital L’Archet, Nice, France
- Dominique Plantaz
- Department of Pediatric Hematology-Oncology, University Hospital of Grenoble, France
- Jean-Hugues Dalle
- Pediatric Hematology Department, Robert Debré Hospital, Paris, France
- Virginie Gandemer
- Department of Pediatric Hematology and Oncology, University Hospital of Rennes, France
- Sandrine Thouvenin
- Pediatric Hematology, University Hospital, Saint Etienne, France
- Nicolas Sirvent
- Pediatric Hematology and Oncology Department, University Hospital, Montpellier, France
- Paul Saultier
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
- Sophie Béliard
- Department of Endocrinology and Nutrition, Timone Hospital, Marseille, France
- Guy Leverger
- Pediatric Hematology Department, Trousseau Hospital, Paris, France
- André Baruchel
- Pediatric Hematology Department, Robert Debré Hospital, Paris, France
- Pascal Auquier
- Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
- Bruno Pannier
- Preventive and Clinical Investigation Centre, Paris, France
- Gérard Michel
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France;Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital, Marseille, France
- DOI
- https://doi.org/10.3324/haematol.2017.176123
- Journal volume & issue
-
Vol. 103,
no. 4
Abstract
The prevalence of the metabolic syndrome among adults from the French LEA childhood acute leukemia survivors’ cohort was prospectively evaluated considering the type of anti-leukemic treatment received, and compared with that of controls. The metabolic profile of these patients was compared with that of controls. A total of 3203 patients from a French volunteer cohort were age- and sex-matched 3:1 to 1025 leukemia survivors (in both cohorts, mean age: 24.4 years; females: 51%). Metabolic syndrome was defined according to the National Cholesterol Education Program’s Adult Treatment Panel III criteria. Metabolic syndrome was found in 10.3% of patients (mean follow-up duration: 16.3±0.2 years) and 4.5% of controls, (OR=2.49; P
